Sign In
Buy MDWD
$14.12
+0.0200 (+0.142%)
At Close: Jul 31, 2026
What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'
09:51am, Monday, 25'th Mar 2024
MediWound (MDWD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
09:26am, Thursday, 21'st Mar 2024
MediWound (MDWD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $1.18 per share a year ago.
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
07:00am, Thursday, 21'st Mar 2024
$19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid ® commercially launched in U.S., Japan, India Potential blockbuster EscharEx ® to begin Phase III in the second half of 20
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
08:00am, Thursday, 14'th Mar 2024
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
09:51am, Wednesday, 06'th Mar 2024
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients
MediWound to Participate in Two Upcoming Investor Conferences
08:00am, Monday, 05'th Feb 2024
YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today
MediWound (MDWD)'s Technical Outlook is Bright After Key Golden Cross
11:17am, Monday, 15'th Jan 2024
After reaching an important support level, MediWound Ltd. (MDWD) could be a good stock pick from a technical perspective.
Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet
07:33pm, Tuesday, 09'th Jan 2024
The consensus price target hints at a 134.8% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
MediWound (MDWD): Strong Industry, Solid Earnings Estimate Revisions
10:31am, Tuesday, 09'th Jan 2024
MediWound (MDWD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
07:00am, Thursday, 28'th Dec 2023
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million Awarded additional $6.7 million to advance NexoBrid as a non-su
Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement Results show EscharEx to be safe and effective, and suggest it can go be
Wall Street Analysts Believe MediWound (MDWD) Could Rally 171.79%: Here's is How to Trade
11:17am, Wednesday, 13'th Dec 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 171.8% in MediWound (MDWD). While the effectiveness of this highly sought-after metric is questionable, the pos
Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?
11:17am, Monday, 27'th Nov 2023
The consensus price target hints at a 223.1% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
